PROTEAN MAPS
LIVE

Serial Number

97515272

Owner

Protean BioDiagnostics Inc.

Attorney

Allison R. Imber

Filing Date

Jul 22, 2022

Add to watchlist:

No watchlists yet
View on USPTO

PROTEAN MAPS Trademark

Serial Number: 97515272 • Registration: 7757271

PROTEAN MAPS is a trademark filed by Protean BioDiagnostics Inc. on July 22, 2022. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Protean BioDiagnostics Inc. (2 trademarks)

7573 Laureate Blvd., Unit 1307
Orlando, FL 32827

Entity Type: 03

Trademark Details

Filing Date

July 22, 2022

Registration Date

April 15, 2025

Published for Opposition

February 25, 2025

Goods & Services

Genetic testing for medical purposes; DNA screening for medical purposes; Medical diagnostic testing, monitoring and reporting services; Medical services; Medical analysis services for the diagnosis and treatment of cancer; Medical services, namely, pathology services for the diagnosis and treatment of disease; none of the foregoing services including monitoring the variables or changes in genomes, DNA, or genes

Medical laboratory services; Medical research services; Scientific laboratory services; Biomedical research services; Chemical research services; Pharmaceutical research services; Genetic testing for scientific research purposes; DNA analysis services for scientific research purposes; Medical and scientific research in the field of immunohistochemistry, in-situ hybridization, molecular diagnostics, genetics, and pathology; Medical and scientific research services, namely, identifying genetic characteristics that affect patients' likelihood or inherited risk of developing cancer and their responsiveness or resistance to cancer treatments and therapies, and the reasons for such likelihood, inherited risk or resistance; Medical and scientific research services, namely, identifying genetic characteristics to predict the prognosis, clinical course, and likelihood of recurrence of patients' cancers, illnesses or malignancies and the effectiveness of treatments and therapies therefor; none of the foregoing services including monitoring the variables or changes in genomes, DNA, or genes

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 15, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 15, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 25, 2025 NPUB
PUBLISHED FOR OPPOSITION
Feb 25, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 19, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 30, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 29, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 29, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 29, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Oct 29, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Oct 29, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 29, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jul 29, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jul 29, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 13, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 13, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jun 13, 2024 ERFR
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Mar 12, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Mar 12, 2024 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 14, 2023 GNFN
FINAL REFUSAL E-MAILED
Dec 14, 2023 GNFR
FINAL REFUSAL WRITTEN
Dec 14, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 16, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 15, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 15, 2023 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Aug 8, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Aug 8, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 16, 2023 GNRN
NON-FINAL ACTION E-MAILED
May 16, 2023 GNRT
NON-FINAL ACTION WRITTEN
May 16, 2023 CNRT
ASSIGNED TO EXAMINER
May 9, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 14, 2022 NWOS
NEW APPLICATION ENTERED
Jul 27, 2022 NWAP